ALGS - Aligos Therapeutics Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-51.52M

Cash

90.84M

Avg Qtr Burn

-17.48M

Short % of Float

2.65%

Insider Ownership

16.25%

Institutional Own.

67.75%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ALG-055009 (THR-β Agonist) Details Non-alcoholic steatohepatitis	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-000184 (Capsid Assembly modulator) Details Chronic hepatitis B	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-097558 Details COVID-19	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-010133 (S-antigen Transport-inhibiting Oligonucleotide Polymer) Details Chronic hepatitis B	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG-125755 Details Chronic hepatitis B, Liver disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.